We are a team of highly experienced market access professionals and leading industry and policy stakeholders from around the world. Our experience spans from within industry, government and strategic consultancy, covering value development and communication, evidence generation and opportunity assessment.
Market access 2.0!
Andrew has a background in Health Economics and Market Access, including roles in Policy Research and Market Access Consulting.
Most recently, he was a Managing Consultant with the Market Access Consulting team at Evidera, with responsibility for global pricing and market access strategies and value communication materials for new medicines. Andrew has worked across a wide range of disease areas and product types, including pharmaceuticals, medical devices and diagnostics. He has completed over 100 HEOR/market access projects, spanning commercial due diligence, global pricing strategies (including reference pricing), clinical/economic evidence development plans, HTA submissions and payer value communication resource development.
Andrew obtained his MSc Health Economics from the University of York, and has led a policy review at the Nova School of Business and Economics, Lisbon, regarding European Commission incentives for the development of orphan drugs.
“I am committed to supporting the development of healthcare innovation with rapid access to strategic insight”
Previously working in commissioning for University Hospitals Birmingham James moved over to market access consultancy with Bridgehead International (acquired by GfK and subsequently IPSOS), working on a variety of access projects including pricing, reimbursement, payer engagement, health economic modelling, due diligence, advisory boards, clinical trial support and payer research. Most recently James has been working as a global market access lead for Norgine, responsible for assets in both hepatology and oncology with the latter from pre-launch to launch planning and execution. James has been responsible for pricing strategy, reimbursement and HTA across Europe, HEOR strategy, payer engagement tools/ rollout, life cycle management and due diligence of potential new assets. James has led and supported on a number of successful HTA submissions in Europe. More recently James has also supported wider commercial activities, leading on brand campaign development and global marketing materials.
“I am driven by striking a fair balance between demand and supply in healthcare systems”
Tammy brings deep perspective in strategic communication, following 18 years of experience in market access strategy and medical/economic writing across numerous therapeutic areas, product profiles and geographies encompassing Europe, UK, USA and Asia.
Specialising in value communication and having freelanced in the space as well as having long-standing senior roles at Wickenstones and the Medical Multimedia Company/Medaxial (now part of Covance), she has conceptualised and led a comprehensive range of projects for a broad spectrum of clients, including value messaging strategy/development, evidence generation, dossiers, economic models, HTA submissions and training/workshops/advisory boards/symposia.
Tammy has a First-Class Degree in Biochemistry from the University of Nottingham (UK) and a post-graduate qualification in information systems/communication.
“I am passionate about value communication, which for me encompasses all of: clever strategy, robust evidence, and clear, precise and succinct presentation.”
Previously working as a retail pharmacist in France, Yasmina moved over to market access consultancy with GfK, subsequently acquired by Ipsos. Over the years, she managed a variety of projects including pricing, reimbursement and access strategies as well as policy trackers and payer and KOL research. Her experience includes managing projects across a range of therapy and product areas including but not limited to orphan diseases, immunology, oncology, cardiovascular, vaccines and medical technology; in a large number of countries across Europe, North America, APAC, LATAM and Middle East.
Recent engagements include secondary and primary payer research for global pharmaceutical and biosimilar, Medtech and vaccines companies across the globe.
Yasmina holds a PharmD from Paris Sud University and a Master’s degree in Marketing management from the ESSEC Business School. She is fluent in French and English and is conversant in Spanish and Arabic.
“I thrive on providing actionable strategic insights to our clients in order to demonstrate their assets’ added value throughout the lifecycle, whilst ensuring it meets with payer’s pricing expectations.”
Maddy is experienced in both qualitative and quantitative research across a wide range of therapy areas, including rare diseases, oncology and haematology. Previous work has involved supporting in the development of a European launch strategy for a new gene therapy, understanding the appropriate economic modelling technique for the long-term extrapolation of overall survival, and developing insights into the European requirements for a phase III clinical development programme.
Maddy has experience in project management, most recently demonstrated through the leadership of a pro bono programme advocating for action to improve health outcomes for sickle cell and young stroke patients.
Maddy completed her BSc Biomedical sciences degree at the University of Manchester, including an industrial placement year in the Central Nervous System Diseases department at Boehringer Ingelheim.
“I am excited to use innovative market research tools in order to help patients gain faster access to potentially life-changing drugs and health technologies”
Bhakti previously worked as a dentist in India and recently completed her MSc in Health Management from City, University of London with distinction. During her masters, she became proficient in conducting qualitative research, systematic and literature reviews. She did her dissertation on ‘Psychological challenges faced by children and adolescents having diabetes’ and worked on various projects on topics including- Striking balance between pharmaceutical innovation and affordability: the key challenges for COVID-19 vaccine in terms of Health Economics, Monoclonal-Antibodies, Telehealth, Checkpoint-Inhibitors. As a part of her masters, she also prepared a consultancy report for a client on the key aspects of the launch of a health technology in Midwest USA focusing on market landscape, entry strategies, pricing, competitor analysis and potential partnerships.
“Being from a medical background and having volunteered with several NGOs, my experiences highlighted the importance, as well as spawned my interest, in providing rapid patient access to newer technologies and drugs. I look forward to working with clients to ensure that ground-breaking innovations reach the people who need them on time.”
Nick’s educational background comprises of a BSC in Biology and a Biotechnology and Enterprise MSc, both awarded at the University of Manchester. During his bachelor’s, Nick gained lab experience while investigating the effects of the parasite Trichuris muris on intestinal myofibroblast activation using fluorescent microscopy. His Masters research focussed on a bioinformatic analysis of Single Nucleotide Polymorphisms within human YKL-40 gene and how these may contribute to disease conditions through alteration of the protein’s tertiary structure. This gave Nick an appreciation of the importance of both laboratory and desk-based research in uncovering scientific breakthroughs.
His Masters also had a heavy focus on the commercial aspects of the life sciences industry in the form of a business project with the aim of bringing a novel electronic biosensor to market. Everything from product design, clinical trial requirements, regulatory processes, market selection and product launch had to be reported on, culminating in a final business pitch. Nick found the process to be highly stimulating and this led him to pursue a career in market access.
“I am passionate about working at the forefront of scientific breakthroughs and am excited to see the impact I can have on the commercialisation of new medicines. I believe I will find it rewarding both intellectually but also morally, knowing that I was able to contribute to the medical access of some of the most neglected diseases.”
Ipek has prior experience as a pharmacist in Turkey and recently completed a MSc in Drug Discovery and Pharma Management from University College London. Ipek is skilled in conducting market research, working with cross-functional teams and co-creating pharma product strategies. She conducted an MSc dissertation in collaboration with Lightning Health and examined the health technology assessment and funding decisions of ATMPs in EU4 and UK. During her undergraduate years, Ipek gained experience through internships in global pharmaceutical companies. She did her graduation training in the health economics, market access and reimbursement department of Janssen Pharmaceuticals. Ipek also studied abroad at the University of Helsinki, Finland where she worked with the pharmaceutical nanotechnology research group at the School of Pharmacy. Ipek aims to bring together pharmaceutical expertise and strategic insights to solve real-world challenges in the market access space.
“There is a chance to understand the strategy and methods involved in positioning a new drug, while considering the numerous factors that come into play throughout the product’s lifecycle. Ultimately, this contributes to addressing unmet medical needs and enhancing the well-being of patients.”
Solomon completed a BSc in Biochemistry and Microbiology at The University of Sheffield and an MSc in Bioinformatics at Queen Mary’s University, London. His masters focused on the bioinformatic analysis of the tumour microenvironment in epithelial ovarian cancer subtypes, which helped define the expression profile of genes and how they contribute to disease progression. This allowed him to understand the importance of exploratory data analysis in making key scientific discoveries.
His experience includes working on quantitative research-driven projects that identify KOL stakeholders across various therapy areas such as oncology, dermatology, gastroenterology and more. Solomon has experience in insight generation from HCP market research to address business questions. Solomon found the process to be very insightful and has led him to pursue a career in market access.
“I have a keen interest in the development of novel therapies and the advancement in technology. I look forward to contributing to the field of market access and working with clients to address the needs of patient populations.”
Abbie completed a MSc in Drug Discovery and Pharma Management at UCL after graduating from the University of Surrey with a BSc in Biomedical Sciences. The research projects she undertook during her studies allowed her to explore a sustainable method of water depopulation and bioremediation as well as analyse the effects on the pricing and accessibility of orphan drugs after a rarity modifier is introduced.
Prior to her academic ventures, Abigail shadowed doctors in hospitals in Tanzania and the UK. These experiences were valuable in shaping her perspective on global healthcare and understanding of the importance of reducing health inequalities by highlighting unmet need.
“The diverse and dynamic nature of this industry excites me for the future of market access for the benefit of both the clients and patients. As more innovation, changes in policy and attitude is introduced, I would love to see how this continues to shape my contributions to the field.”
Charlotte has specialised in healthcare market research for over ten years. She has worked in both consultancy and academia across multiple therapeutic areas including infectious disease, chronic disease and acute illness. An experienced project manager, Charlotte has conceptualised and led a diverse portfolio of projects across a wide geographic landscape, working with a diverse range of stakeholders including key opinion leaders, clinicians, payers, market access leads, patients and carers. Charlotte has a strong background in public health and healthcare service delivery and design, with a particular focus on understanding the patient journey and experience, and identifying the optimal positioning of diagnostic tools and therapies in the patient pathway with the aim to improve patient care and outcomes. Charlotte has a PhD in Children’s Health from the University of Exeter. She is an experienced qualitative researcher, with a desire to improve patient pathways and ultimately patient outcomes.
“I am passionate about working closely with key stakeholders, particularly patients, to understand where new diagnostics or therapies can have the biggest impact on the patient pathway and outcomes. My goal is to produce evidence-based research that informs healthcare decision making with the patient at the centre of the process and solution.”
Stefania is an experienced payer and KOL recruitment professional, having spent over a decade in healthcare market access consulting. She has extensive experience managing global payer and clinician panels for healthcare research and in developing, supporting, and implementing online, on-demand stakeholder insight technologies. Stefania most recently worked at Market Access Transformation as a senior global payer relationship manager in New York (USA) and London (UK), and before that she was at GfK Market Access (now IPSOS) in London overseeing the payer liaison team. Before moving into the healthcare industry, she worked in the qualitative research unit at NatCen, Britain’s largest independent social research organisation. In Rome (Italy), Stefania worked at Consorzio GAIA S.p.A. as a project manager on international environmental cooperation projects in the Balkans and East Asia.
She earned a B.A. in International Business and a diploma in Accounting and has completed project management training.
“I am committed to connecting manufacturers with the correct payers and clinicians, producing robust research that enables patients access to leading therapies”
Shavonne is a Finance Professional with many years of experience that spans across various industries. Contributing as part of the leadership team, assisting and providing rapid solutions to operational processes.
Shavonne’s bespoke hands-on approach always offers the best practise available, whilst enabling businesses to thrive and grow organically at their own pace. By providing a structurally sound accounting framework, each department can work together harmoniously while still configuring to different levels of management.
“While it’s important to hit deadlines and regiment workflows, I’m a great believer in creating a happy workforce – only then can great staff be retained to perform consistently, resulting in greater patient access to innovative health technologies.”
Charlotte is a communications professional with over 10 years pharma industry and healthcare communications experience.
Charlotte’s breadth of experience ranges from global corporate communications and crisis management to product communications, policy, patient advocacy, internal communications and employee engagement.
“I am passionate about the power of great communication and am motivated by delivering impactful programmes that benefit the most important stakeholder of all, patients”
As Chairman of Bridgehead International, a market access consultancy acquired by GfK and subsequently IPSOS, David has spent the last two decades championing an effective dialogue between industry and payers. He is concerned that innovations should find their right place in the diagnosis and treatment of patients and that benefits from research are fully realised.
“I am using my experience to establish, with my colleagues, an efficient platform for product pricing to ensure timely access for patients.”
As Founder and Director of Bridgehead International, an international pricing consultancy divested to GfK, Fiona helped clients to identify, assess and adopt innovative technologies. She uses her experience to support the development of new drugs and medical devices for the benefit of innovators, health systems and patients.
“I see a real need to improve the efficiency of collection and analysis of market access data, from rapid early insights to in-depth studies”
Peter is an experienced senior consultant with expertise across the spectrum of pharmaceutical commercial activities.
In Peter’s past experience he has been the UK Pharma General Manager (Fujisawa, now Astellas), and EU/Global Managing Director at Pharma Agencies (Grey, ESL, Solaris).
Peter has specific recent UK and EU reimbursement/market access experience across a variety of disease areas and specialises in combining the activities of multiple functions within a life sciences company.
Jim Furniss is an independent consultant advising companies on market access for pharmaceuticals in Europe, North America and the rest of the world.
Jim was a senior official in the UK Department of Health, responsible for the operation of the Pharmaceutical Price Regulation Scheme and for the NHS drug budget. He was also a member of the European Commission’s Pharmaceutical Pricing Transparency Committee.
Jim has subsequently spent 20 years in consultancy in the healthcare and pharmaceutical industry, working on a large number of pharmaceutical pricing, reimbursement and market access projects. This has included all major therapy areas, but with an emphasis on oncology and orphan drugs , including treatments for multiple myeloma – specifically lenalidomide and bortezomib.
Stuart has over thirty years’ experience in the pharmaceutical industry. During this time, he has worked across sales, marketing, public affairs and market access. Stuart started his pharmaceutical career as a Regional Manager with Servier before moving to Astra (before the merger with Zeneca) where his roles included NHS Facilitator (an early market access role) and regional controller.
Stuart had a number of roles at Pfizer, starting in Sales Management before setting up the Market Access team, one of the first in the UK at the time. Stuart then moved to Pfizer’s Government Affairs team in Brussels, before joining Eli Lilly as Head of European Public Affairs. There he was responsible for a cross-functional team covering Government Affairs, Communications, Policy Development, Patient Advocacy and Corporate Responsibility.
More recently, Stuart has focussed on rare diseases. Firstly with Synageva as VP, European Market Access & Government Affairs, where he took an ultra-orphan medicine from phase III results to being ready for pricing & reimbursement submission in all major markets in nine months. He then joined Akcea as Head of Global Market Access, Pricing and Reimbursement and established the function at global and country level, prior to the launch of an ultra-orphan in mid-2019.
Stuart is now working as an Independent Consultant supporting biotech companies looking to commercialise medicines for rare diseases internationally. His work includes commercial strategy & sequencing, global market access capacity and competency development, market access due diligence and talent acquisition.
Dr Frances Macdonald has a broad background in product development, market access and commercial leadership.
Dr Macdonald was a member of the Scottish Medicines Consortium (SMC), the Scottish HTA agency, for 7 years as the lead industry representative, sponsored by the Association of the British Pharmaceutical Industry (ABPI). She chaired the joint SMC/industry user group forum, ensuring industry input and collaboration on the evolution of SMC processes and methods.
Earlier in her career, Dr Macdonald spent 7 years leading European Global Health Economic and Outcomes Research groups in Syntex (UK) followed by Roche (Basel). Within Roche, her team provided strategic advice plus operational support on health economics and pricing throughout the company, from basic research through to the commercial affiliates.
Dr Macdonald has also worked in a range of roles in clinical development, including Project Management, Clinical Pharmacology, and European Regulatory Affairs and led a Global Lifecycle team within the Roche oncology franchise. Frances also established and led the UK and Irish commercial subsidiary of Actelion as UK Managing Director. Dr Macdonald holds a PhD in Physiology from Glasgow University.
Chris brings with him 25+ years practical and academic experience within the pharmaceutical industry, across both Marketing and R&D having been Director of Global Pricing and Market Access (Oncology) at Astra Zeneca, Director Health Economics, Pricing, Reimbursement and Access at Allergan, Commercial Planning Manager at Fisons, and Portfolio Planning Manager at Novartis in Switzerland.
For the past 10 years he worked in Consultancy (Bridgehead International, GfK, and Ipsos) and in 2023 founded TealeHealth Ltd, a consultancy providing expert Advisory, Access, and Analytic support on Advanced Personalised Therapies.
Chris brings significant experience of identifying and overcoming hurdles along the whole value chain – clinical development, manufacturing, distribution, regulatory assessment, health technology assessment, market access, pricing, marketing, and product uptake. He specialises in helping companies understand the value and sustainability of their differentiation relative to the competition and the evidence requirements to underpin this.
Chris has a mathematics and operational research background having studied at Newcastle and Loughborough universities, and at INSEAD Business School in France. He is an occasional lecturer on health economics and pharmaceutical pricing and reimbursement at Kings College London and University of California (San Diego), a member of ISPOR (International Society for Pharmacoeconomics and Outcomes Research) and PMSA (Pharmaceutical Management Science Association).
Dr Owens served as the Vice President of Medical Management and Policy at Independence Blue Cross (IBC) for 22 years with responsibilities for medical and pharmacy management, technology evaluation and medical policy.
Among his accomplishments at IBC was the development of their medical policy process with on-line access, and the launch of a coordinated care management approach to medical and pharmacy management. He was also in charge of the 2006 launch of FutureScripts, IBC’s wholly owned Pharmacy Benefit Manager (PBM). Forming his own consulting practice in 2007, Dr Owens provides strategic and tactical consulting services to a wide range of clients including pharmaceutical manufacturers, device manufacturers and other developers of new technology.
He has presented extensively on managed care, including at conferences of the Academy of Managed Care Pharmacy (AMCP), the National Association of Managed Care Physicians (NAMCP), and the Association for Value-Based Cancer Care. He has written 120 articles and editorials on managed care, pharmacy, and biotechnology, which have been published in American Health and Drug Benefits, The Journal of Managed Care Medicine, The American Journal of Managed Care, Journal of Managed Care and Speciality Pharmacy and Disease Management.
Dr Owens is the Past Chair of the Arthritis Foundation of Eastern PA and he was a former member of the Foundation’s Northeast Regional Board of Directors. Dr Owens was the first physician to serve (2014-2018) as a Board member of the Academy of Managed Care Pharmacy.
Our values inform our decisions and behaviours, shape our culture, and are used everyday to guide us when working to achieve our mission.
We empower our
team to thrive
Motivating | Inclusive | Knowledgeable
We support our team to grow, both professionally and personally, with a strong emphasis on maintaining a healthy work-life balance. We genuinely appreciate every individual team member, and aim to inspire a sense of purpose in all their work.
Committed | Inspired | Understanding
We are committed to supporting the life sciences sector, to improve patient care in areas of unmet need. We extend our values and aspirations to our clients, so that together, we understand and appreciate the needs of the patients who benefit from our research.
We achieve things that
we are proud of
Collaborative | Experienced Courageous
We empower clients our with technology and support them with our expertise. As a trusted partner, we act with uncompromising integrity and dedication, and can be relied upon to deliver high quality insights and informed advice.
We have fun
Friendly | Supportive | Vibrant
We nurture an environment where we encourage, appreciate and take care of each other; because fun happens when people are trusted. We are selective when finding new people to join us, to ensure we maintain the welcoming and inclusive culture.